CAL-101 and a 26% response rate

[Guest guest]

I note from the ASCO abstract on CAL-101 that there were

significant adverse side effects and a poor response rate of

only 26%, which is the lowest I've seen.

I suppose these results are typical for an early version of

a drug targeting a new pathway, but still disappointing for

us fighting an incurable disease.

We were all hoping for a home run, sort of a Gleevic-like

response for CLL. Not to be.

The side effects surprise me, as I had none of them (except

elevated liver enzymes): pneumonia (24%), neutropenia (24%),

thrombocytopenia (7%), neutropenic fever (7%), anemia (6%)

and ALT/AST increase (6%).